Scott Page Launches Life Settlement Litigation, Fraud Detection, and Expert Witness Services
"Fraud in life settlements is on the rise — from fabricated medical records and manipulated life expectancy reports to policy valuations deliberately crafted to mislead investors," said Page. "Recent STOLI rulings have only compounded the damage, harming investors while allowing the questionable actions of carriers, agents, insureds, and intermediaries to go unchecked. Such actions threaten the very integrity of the industry I helped build — and that is why I am stepping forward now."
Recognized as a trusted authority and the go-to source for credible, unbiased data in the life settlement market, Page brings unparalleled insight into complex transactions. With more than 30 years of direct experience, he is uniquely qualified to:
- Provide expert witness services in complex life settlement litigation
- Uncover medical and transactional fraud with precision
- Expose collusion between agents, brokers, and providers
- Determine the true market value of life insurance policies
- Build and fortify winning strategies for both plaintiff and defense cases
"Life settlement transactions are often manipulated long before they reach the market," Page noted. "My role is to find the smoking gun quickly and help legal teams build airtight cases — whether the issue is fraud, valuation abuse, collusion, or lack of disclosure."
About
For more information or to request a confidential consultation, visit www.scottpage.com.
About ScottPage.com
Press Contact:
View original content to download multimedia:https://www.prnewswire.com/news-releases/scott-page-launches-life-settlement-litigation-fraud-detection-and-expert-witness-services-302528886.html
SOURCE ScottPage.com
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Taiwan Brings Herbal Heritage and Modern Innovation to SupplySide Global 2026
- JST Buyback & Burn Upgrade: GasFree Revenue and $20.34M Surplus Injected as JUST's Ecosystem Trio Solidifies JST Token Value
- ESMO 2026: NUBEQA® (darolutamide) Plus ADT and Radiation Therapy Reduces Risk of Metastasis or Death by 58% in Prostate Cancer Patients at High Risk of Recurrence
Create E-mail Alert Related Categories
PRNewswire, Press ReleasesSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!





Tweet
Share